⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 26, 2024Open Access

FIGURE 3 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Rhonda L. Bitting Janet A. Tooze Michael Goodman Donald C. Vile Jessica M. Brown Christopher Y. Thomas Morgan Neve Mitra Kooshki Safoa Addo Pierre L. Triozzi Purnima Dubey

View Full Paper

Ask AI

Bookmark

Share

Abstract

miRNAs detected at baseline, after three cycles, and after six cycles of treatment in the urine (left) and plasma (right), separated by responders (CR+PR, solid circles) versus nonresponders (SD+PD, open circles). Plot is mean value and error bars show ± 1 SE. Y-axis is RQ, X-axis is baseline (bsl), after cycle 3 (C3), and after cycle 6 (C6).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bitting et al. (2024) studied this question.

synapsesocial.com/papers/68e779deb6db6435876ee304 https://doi.org/10.1158/2767-9764.25288988.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1FIGURE 2 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma2024
2TABLE 3 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma2024
3TABLE 3 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma2024
4Supplementary figure S1 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma2024
5Supplementary figure S1 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma2024